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        Mucosal-associated invariant T cells (MAITs) 
are a unique   “  innate  ”   T cell population that ex-
presses an invariant mV    19 TCR     in mice and 
the homologous hV    7.2 in humans (  1  ). With 
the exception of preferential localization in the 
intestine, MAIT cells bear striking similarities 
to the extensively studied   i  NKT cells that ex-
press mV    14 in mice and hV    24 in humans 
(  2, 3  ). Functional analysis of MAIT cells has been 
diffi   cult because of the paucity of this popula-
tion in mice. However, studies using recently 
derived V    19  i   TCR transgenic mice have shown 
that MAIT cells have a memory or activated 
phenotype (CD44  hi  , CD45RB  lo  , CD25  lo  , and 
CD62L  neg  ) and are ICOS  int-hi   (  4  ). Like   i  NKT 
cells, MAIT cells expand poorly in vitro upon 
TCR ligation, but rapidly release IFN-    , IL-4, 
-5, and -10 (  4, 5  ). Although the function of 
MAIT cells has yet to be fully elucidated, it has 
been speculated that they serve as regulatory 
cells in a feedback loop controlling gut IgA 
production (  2, 3  ). Additionally, MAIT cells 
have been implicated in the regulation of auto-
immune infl  ammation in a mouse EAE model 
(  5  ). More specifi  cally, adoptive transfer of trans-
genic MAIT cells inhibited the induction and 
progression of EAE and was accompanied by 
reduced production of infl  ammatory cytokines 
and increased production of IL-10. Interest-
ingly, the increased IL-10 was accounted for, at 
least in part, by an ICOS-mediated interaction 
between MAIT cells and B cells. Thus, accu-
mulating evidence suggests that MAIT cells are 
potent immune regulatory cells that can shift 
the balance between homeostasis and autoim-
mune responses. 
  Whereas NKT cell development is CD1d 
dependent, MAIT cell development and/or 
expansion is dependent on MHC-related pro-
tein I (MR1), B cells, and gut commensal 
fl  ora. In addition, we have shown that select 
MAIT cell hybridomas are activated by cells 
CORRESPONDENCE  
  Ted H. Hansen: 
 hansen@wustl.edu
  Abbreviations used: BFA, 
brefeldin A; CMA, concanamy-
cin A; CRT, calreticulin; 
MAIT, mucosal-associated 
invariant T cell; MFI, mean 
fl  uorescence intensity; MIIC, 
MHC class II compartment; 
MR1, MHC-related protein I; 
sh, small hairpin; si, small 
interference. 
      The online version of this article contains supplemental material.   
  MR1 uses an endocytic pathway to activate 
mucosal-associated invariant T cells 
    Shouxiong     Huang  ,    1       Susan     Gilfi  llan  ,    1       Sojung     Kim  ,    1       Bruce     Thompson  ,    1     
  Xiaoli     Wang  ,    1       Andrea J.     Sant  ,    2       Daved H.     Fremont  ,    1       Olivier     Lantz  ,    3     
and   Ted H.     Hansen      1     
  1  Department of Pathology and Immunology, Washington University, St. Louis, MO 63110 
  2  Department of Microbiology and Immunology, University of Rochester, Rochester, NY 14642 
  3  Laboratoire d  ’  Immunologie and Institut National de la Sant  é   et de la Recherche M  é  dicale U520, Institut Curie, 
75005 Paris, France   
  Like CD1d-restricted   i  NKT cells, mucosal-associated invariant T cells (MAITs) are   “  innate  ”   
T cells that express a canonical TCR     chain, have a memory phenotype, and rapidly secrete 
cytokines upon TCR ligation. Unlike   i  NKT cells, MAIT cells require the class Ib molecule MHC-
related protein I (MR1), B cells, and gut fl  ora for development and/or expansion, and they 
preferentially reside in the gut lamina propria. Evidence strongly suggests that MAIT cell 
activation is ligand-dependent, but the nature of MR1 ligand is unknown. In this study, we 
defi  ne a mechanism of endogenous antigen presentation by MR1 to MAIT cells. MAIT cell 
activation was dependent neither on a proteasome-processed ligand nor on the chaperoning 
by the MHC class I peptide loading complex. However, MAIT cell activation was enhanced by 
overexpression of MHC class II chaperones Ii and DM and was strikingly diminished by silenc-
ing endogenous Ii. Furthermore, inhibiting the acidifi  cation of the endocytic compartments 
reduced MR1 surface expression and ablated MAIT cell activation. The importance of the 
late endosome for MR1 antigen presentation was further corroborated by the localization of 
MR1 molecules in the multivesicular endosomes. These fi  ndings demonstrate that MR1 
traffi  cs through endocytic compartments, thereby allowing MAIT cells to sample both endo-
cytosed and endogenous antigens. 1202 ANTIGEN PRESENTATION PATHWAY OF MR1 | Huang et al.
presentation of the self-ligand (  2, 6  ). In this study, we used 
these hybridomas to demonstrate that MAIT cell activation by 
MR1 does not require proteasome function, TAP, tapasin, or 
CRT. However, MR1 physically associates with Ii and DM, 
and this association promotes MR1 localization in endosomal 
compartments. More strikingly, we present multiple lines of 
evidence showing that both MR1 traffi   cking  through  late 
endocytic compartments and the presence of Ii are critical for 
MAIT cell activation, but have less impact on MR1 surface 
expression. Thus, MR1 appears to use an antigen presentation 
pathway similar to MHC class II and/or CD1, potentially al-
lowing it to sample endocytic compartments containing endog-
enous and microbial antigens. 
    RESULTS   
  MR1 surface expression and MAIT cell activation 
are TAP independent 
  MR1 message (  7  ) and protein (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20072579/DC1) are 
ubiquitously expressed in various cell lines and tissues. How-
ever, we and others have thus far failed to identify cells ex-
pressing endogenous MR1 on the cell surface using multiple 
anti-MR1 antibodies or that are capable of MAIT cell activation 
(  21  ) and (unpublished data). These combined fi  ndings sug-
gest that, unlike the constitutively expressed CD1 molecules 
overexpressing transfected MR1 protein in a manner that 
can be blocked by either mAb to the TCR or MR1 (  2, 6  ). 
In these in vitro assays, several lines of evidence suggested 
that MR1 presents a ligand to MAIT cells (  6  ). Intriguingly, 
the     1 and     2 domains of the MR1 molecule are highly 
conserved among mammals, with     90% identical residues 
between human and murine MR1 proteins (  7  ). This degree 
of homology is much higher than     60  –  70% for the CD1 
and class Ia molecules, and strongly suggests that MR1 pre-
sents an evolutionarily conserved ligand (  8  ). However, the 
chemical nature of the MR1 ligand remains unknown. In-
terestingly, recent reports suggest that the synthetic glycolipid 
    -mannosyl ceramide and its derivatives can diff  erentially 
activate V    19  i   T cells (  9, 10  ). However, comparisons be-
tween MR1 and class Ia molecules indicate that the putative 
ligand-binding groove of MR1 is more homologous to classical 
class I molecules and contains more hydrophilic or charged 
residues than do CD1 molecules (  8  ). Thus, it remains criti-
cal to defi  ne the physiological ligands presented by MR1. 
  Because pathogens can reside in disparate intracellular 
compartments, the immune system has evolved distinct anti-
gen presentation pathways for sampling various intracellular 
organelles. MHC class Ia molecules are typically loaded within 
the ER with peptides derived from proteasome-digested pro-
teins and transported into the ER lumen by TAP. Within the 
ER lumen, peptide loading by class I is facilitated by physical 
association with TAP, as well as other members of the peptide-
loading complex, e.g., tapasin, calreticulin (CRT), and ERp57 
(  11  ). In contrast, nascent MHC class II molecules physically 
associate with the invariant chain (Ii), which prevents ligand 
binding in the ER and promotes traffi   cking to a late endo-
somal compartment called the MHC class II compartment 
(MIIC) (  12, 13  ). Within the MIIC, the class II molecule asso-
ciates with DM, which facilitates the release of an Ii-associated 
peptide and binding of an endosomal peptide (  12, 14  ). 
  Extending the MHC paradigms, CD1 isoforms have 
evolved elaborate presentation pathways to sample the lipid 
content of disparate organelles, elucidated in part with CD1-
overexpressing cells (  15  ). Specifi  cally, CD1 molecules bind a 
self-lipid in the ER, transit to the cell surface, and then recy-
cle to bind lipid in an endocytic compartment. Interestingly, 
for the CD1d isoform, physical association with Ii plays a re-
dundant role with sorting motifs in the CD1d tail, either of 
which promotes endosomal traffi   cking to bind appropriate 
lipids (  16  ). Distinct lipids appear to be loaded onto diff  erent 
CD1 isoforms depending on the specifi  c endosomal compart-
ment in which loading occurs; as with MHC molecules, cha-
perones and enzymes are critical factors (  15  ). Interestingly, a 
high percentage of   i  NKT hybridomas are autoreactive, de-
tecting either an unknown self-ligand or the recently identi-
fi   ed self-lysosomal glycolipid iGb3 (  17  –  19  ). Furthermore, 
presentation of self-CD1d ligands has been speculated to play 
a central part in the NKT cell development, infections, and 
autoimmunity (  19, 20  ). 
  Like   i  NKT cells, select MAIT cell hybridomas can be acti-
vated by transfected cells expressing high levels of MR1 with 
    Figure 1.     MR1 surface expression and MAIT cell activation are not 
dependent on TAP expression.   The  TAP-defi  cient cell TAP     /     and  the 
TAP-rescued cell were transduced with wild-type mMR1 or the mMR1/L  d  
chimeric molecule. (A) Thin lines indicate the background with secondary 
antibody only; thick lines indicate the staining with annotated antibodies. 
(B) Activation of MAIT cell hybridoma 6C2 (mean   ±   the SD) was observed 
with no additional antibody (No Ab), anti-MR1 blockade, or isotype-
matched irrelevant Ab (34  –  2-12), as applied in other MAIT cell activation 
assays. Data are representative of two experiments.     JEM VOL. 205, May 12, 2008 
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MAIT cell activation. Thus, MR1 surface expression and 
MAIT cell activation are clearly TAP independent. 
  MR1 surface expression and MAIT cell activation 
do not require tapasin, CTR, or class Ia molecules 
  Ligand binding of MHC class Ia is facilitated by its associa-
tion with the peptide-loading complex consisting of TAP, 
tapasin, CRT, and ERp57 proteins (  11, 23  ). Of particular 
note, both tapasin and CRT can associate with class Ia in the 
absence of TAP, and both of these ER chaperones promote 
assembly of class I heavy chains with peptide and     2m (  11  ). 
Therefore, it was of interest to examine whether these ER 
chaperones might also aff  ect MR1 expression and MAIT 
cell activation. Cell lines defi  cient for tapasin or CRT were 
transduced with intact or chimeric MR1 and further tested 
for MR1 surface expression and MAIT cell activation. Re-
sults showed that neither tapasin (  Fig. 2, A and B  ) nor CRT 
(  Fig. 2, C and D  ) aff  ected MR1 expression or MAIT cell 
activation.   To determine whether class Ia molecules infl  uence 
MR1 expression and MAIT cell activation, intact or chimeric 
MR1 was introduced into fi  broblasts that were genetically 
defi  cient for K  b   and D  b   expression (KODO). As shown in 
  Fig. 2 (E and F)  , class Ia  –  defi  cient or wild-type cells ex-
pressed similar levels of intact and chimeric MR1 and stimu-
lated MAIT cells equally well. This fi  nding indicates that MR1 
is unlike the class Ib molecules Qa-1 and HLA-E that bind and 
present leader peptides of class Ia molecules. Furthermore, 
this fi  nding also suggests that the low level of surface MR1 
expression does not result from an unfavorable competi-
tion with class Ia molecules for ER chaperones or ligands. 
(  15, 17  ), MR1 requires an unknown regulatory mechanism 
for surface expression. However, select MAIT cell hybrid-
omas are activated by various transfectants overexpressing 
MR1 (unpublished data), thus providing a model system for 
studying how an endogenous antigen is presented to MAIT 
cells. As noted, such a model system has interesting parallels 
with CD1d presentation of self-ligands to   i  NKT cells (  17  ). 
  Using this model system, we fi  rst addressed the role of 
TAP for MR1 expression and MAIT cell activation. Interest-
ingly, MR1 molecules were previously detected in associa-
tion with TAP and the peptide-loading complex at levels 
similar to classical class Ia molecules (  22  ). However, MAIT 
cells were found to be more abundant in TAP-defi  cient mice 
(  1, 2  ). To test the role of TAP in MAIT cell activation, 
TAP1-defi  cient cells were transduced with retrovirus con-
taining a cDNA-expressing intact mMR1 molecules or an 
mMR1/L  d   chimera. This chimera has the     1/    2 domains of 
mouse MR1 and the     3 domain of L  d   molecule (  22  ). Its in-
clusion was based on the fact that ligand binding should be 
unaltered, yet its surface expression is higher than intact 
mMR1, possibly because of better interaction with     2m (  22  ). 
As shown in   Fig. 1 A  , the absence or presence of TAP did not 
aff   ect the expression of either intact or chimeric mMR1 
molecules.   As a control, expression of H-2K  b   was shown to 
be TAP dependent. In spite of their disparate levels of ex-
pression, neither intact mMR1 nor the MR1/L  d   chimera was 
dependent on TAP for MAIT cell activation (  Fig. 1 B  ). Im-
portantly, in these functional assays, MAIT cell activation was 
shown to be MR1 specifi  c using control cells not transduced 
with MR1 and a mAb specifi  c for folded MR1 to block 
    Figure 2.     MR1 surface expression and MAIT cell activation are not dependent on tapasin, CRT, or class Ia molecules.  The  tapasin-defi  cient cell 
(Tpn     /    ), tapasin-rescued cell (Tpn     /   Tpn),  CRT-defi  cient cell CRT     /     (K42), and K  b   D b   knockout cells (KODO) were transduced with mMR1 or the mMR1/L  d  
chimeric molecule and tested for MR1 surface expression (A, C, and E) or MAIT cell activation (B, D, and F; shown as the mean   ±   the  SD).   1204 ANTIGEN PRESENTATION PATHWAY OF MR1 | Huang et al.
cules, MR1 expression and MAIT cell activation are protea-
some independent. 
  Ii and DM are associated with MR1 and enhance MAIT 
cell activation 
  Because class I chaperones were not required for activation of 
MAIT cells by MR1, we asked whether class II chaperones 
provide assistance. To determine whether MR1 expression 
  MR1 surface expression and MAIT cell activation 
is proteasome independent 
  The ubiquitin  –  proteasome pathway is the principle mecha-
nism by which cytoplasmic proteins are turned over and 
peptide ligands are generated for binding to MHC class Ia 
molecules. Accordingly, inhibition of proteasome function 
blocks peptide generation and antigen presentation by MHC 
class Ia molecules to CD8  +   T cells (  24  ). Although TAP inde-
pendence makes it less likely that MR1 binds a proteasome-
cleaved peptide, it does not formally rule it out because there 
are examples of class Ia presentation of TAP-independent, but 
proteasome-dependent, peptides (  25  ). To determine whether 
MR1 expression and MAIT cell activation are proteasome-
dependent, MR1-transduced LM1.8 and WT3 cells were 
treated with lactacystin or NLVS (NIP-L  3  VS) (  26  ). Neither 
of these proteasome inhibitors had an impact on MR1 ex-
pression (  Fig. 3 A  ) or MAIT cell activation (  Fig. 3 B  ), al-
though both inhibitors reduced expression of class Ia molecules 
K  b   and L  d   (  Fig. 3 A  ) and inhibited activation of the T cell hy-
bridoma L3, which is alloreactive for the L  d   molecule (  Fig. 3 B  ).   
In these comparisons, we also included the drug brefeldin 
A (BFA), which blocks protein transport past the mid-Golgi 
complex (  27  ). Overnight treatment with BFA had similar 
eff  ects on MR1 and class Ia L  d   or K  b   cell surface expression, 
suggesting that they have similar rates of surface turnover 
(  Fig. 3 A  ). As expected, activation of both MR1- and L  d  -
reactive hybridomas was ablated after overnight BFA treat-
ment, indicating that surface expression of and consequent 
T cell activation by both MR1 and class Ia molecules re-
quires protein transport from the ER to the Golgi complex. 
However, these assays demonstrate that, unlike class Ia mole-
    Figure 3.     Proteasome function is not required for MR1 surface 
expression or MAIT cell activation.   The mMR1-, L  d  -, or K  b -expressing 
LM1.8 cells were treated with the specifi  c proteasome inhibitors Lacta-
cystin (Lac; 25   μ  M) and NLVS (50   μ  M), or with the drug BFA (10   μ  g/ml), 
using DMSO as a vehicle control. (A) Surface molecules were stained 
with indicated antibodies. The percentage of the remaining MHC mole-
cules on the surface was calculated by dividing mean fl  uorescence in-
tensity (MFI) of the inhibitor-treated cells with that of the control. 
(B) MAIT cell hybridomas 6C2 and 8D12 responding to inhibitor-treated 
cells were compared with L  d  -reactive hybridoma L3. T cell activity was 
shown as the percentage to that of the control. Data shown are repre-
sentative of two experiments.     
    Figure 4.     Ii and DM are associated with MR1 and facilitate MAIT 
cell activation.  Ltk       cells overexpressing of A  d  , Ii, and DM (  13  ) were 
transduced with mMR1. (A) Thick lines indicate the staining with anno-
tated antibodies; thin lines indicate the negative control with secondary 
antibody only. Numbers indicate MFI of antibody staining. These data are 
representative of multiple experiments. (B) Coprecipitation of Ii with MR1 
with indicated antibodies using the MR1-defi  cient fi  broblast FMR1     /     as 
a negative control and     -actin staining as a loading control. These experi-
ments were repeated two times with similar results. (C) Coprecipitation of 
MR1 with DM, but not with MHC class II molecule I-A  d  . (D) Activation of 
MAIT hybridomas 6C2 and 8D12 mean   ±   the SD) with cells overexpressing 
Ii was quantifi  ed using a standard curve generated with recombinant 
mouse IL-2. Nontransduced indicates cells without MR1 transduction; No 
Ab indicates no additional antibody. Eight experiments were done, with 
similar  results.   JEM VOL. 205, May 12, 2008 
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enhanced activation of both MAIT hybridomas tested. It is 
intriguing that the presence of DM appears to accentuate 
both the physical association of MR1 with Ii, as well as 
the MAIT cell activation. However, overexpression of Ii 
alone clearly augments MAIT cell activation in these cell 
lines, possibly by facilitating MR1 traffi   cking to an endo-
somal compartment. 
  Ii causes partial redistribution of MR1 to late 
endocytic compartments 
  We demonstrated that MR1-specifi   c activation of MAIT 
cells is enhanced by overexpression of Ii. It is known that Ii 
facilitates the transport of class II molecules to endocytic 
compartments (  12, 13  ). To test whether Ii facilitates the 
transport of MR1 molecules from the ER to the endocytic 
pathway, we generated an mMR1.EGFP fusion protein by 
linking EGFP to the C terminus of mouse MR1 and ex-
pressed mMR1.EGFP in the cells with diff  erent Ii expression 
levels. Subcellular localization of MR1 showed that MR1 
colocalized more with Lamp1 in cells overexpressing Ii. 
Pearson  ’  s coeffi   cient of colocalization of MR1 and Lamp1 
was higher in Ii-expressing cells than the parental cells (  Fig. 5 A  ).   
Importantly, the percentage of MR1 that colocalized with 
Lamp1 protein increased in Ii-expressing cells with statistical 
signifi  cance (  Fig. 5 B  ). These results indicate that Ii facili-
tates the partial redistribution of MR1 from the ER to late 
endocytic compartments. 
  Late endosomal compartments are critical for MR1 
traffi  cking and MAIT cell activation 
  The evidence presented thus far that endosomal traffi   cking 
enhances MAIT cell activation was obtained with L cells. 
was aff  ected by overexpression of Ii and DM, intact MR1 was 
introduced into Ltk    –    cells expressing class II and Ii (A  d  .gIi), or 
class II, Ii, and DM (A  d  IiDM) (  13  ). As shown in   Fig. 4 A  , the 
overexpression of Ii with or without DM had little eff  ect on 
MR1 expression, but a signifi  cant eff  ect on class II expression.   
To determine whether Ii and/or DM could be detected in 
physical association with MR1, coimmunoprecipitation ex-
periments were performed on the above Ltk    –    transfectants. In 
this experiment, Ii was precipitated with mAb In-1 or DM was 
precipitated with a rabbit polyclonal antiserum (  28  ) and the re-
spective precipitates were blotted with mAb 4E3 to detect 
MR1. As shown in   Fig. 4 (B and C)  , signifi  cant amounts of 
MR1 coprecipitated with Ii in lysates of the A  d  .gIi and A  d  IiDM 
cell lines, and signifi  cant amounts of DM precipitated with 
MR1 in a lysate of the A  d  IiDM cell line. In parallel, the endog-
enous Ii and DM were also associated with MR1 in the mouse 
B cell CH27 (unpublished data). Importantly, in vitro mixing 
experiments demonstrated that these associations with MR1 
did not occur after cell lysis (unpublished data). In contrast to 
its association with Ii and DM, MR1 was not detected in asso-
ciation class II (  Fig. 4 C  ). These disparate associations are of 
considerable interest in light of previous fi  ndings that CD1d is 
coprecipitated with Ii and MHCII (  29  ) in humans and Ii alone 
in mice (  16, 20  ). It is also important to note that the tail of 
MR1 lacks known sorting motifs like the ones on tails of CD1 
isoforms (  16  ). Thus, MR1 may be more dependent on Ii for 
endosomal traffi   cking. 
  To determine whether Ii or DM might impact MAIT 
cell activation in a manner independent of increased surface 
expression, these cell lines were tested for their ability 
to activate MAIT cell hybridomas. As shown in   Fig. 4 C  , 
the overexpression of Ii and both Ii and DM signifi  cantly 
    Figure 5.     MR1 is partially redistributed into Lamp1  +   compartments in cells overexpressing Ii.   Ii-overexpressing cells were transduced with mMR1.
EGFP and stained with rat anti  –  mouse Lamp1. (A) The colocalization of MR1 (green) with Lamp1 (red) are analyzed using the imaging analysis program 
Volocity and are plotted to the right. The r values for each cell type were obtained by averaging the Pearson  ’  s coeffi  cients of colocalization from multiple 
cells (  n   indicates the cell number). The signifi  cance (P) of the r value was examined using a paired Student  ’  s   t   test. Bars, 5   μ  m. (B) The percentage of MR1 
localization in the late endocytic compartment (Lamp1  +  ) was analyzed and shown to be signifi  cantly higher with Ii overexpression. Data represent the 
mean   ±   the SEM from multiple cells (  n  ). The P values were obtained using a paired Student  ’  s   t   test.   1206 ANTIGEN PRESENTATION PATHWAY OF MR1 | Huang et al.
  Interference of endogenous Ii expression reduces 
MR1 surface expression on B cells and inhibits MAIT 
cell activation 
  We next assessed the consequences of inhibiting endogenous 
Ii expression in a B cell line, the putative MAIT cell APC. 
To this end, a small hairpin RNA (shRNA) expression vec-
tor targeting diff  erent fragments of mouse Ii was transduced 
into the B cell line CH27.mMR1 (  Fig. 7   and Fig. S4, avail-
able at http://www.jem.org/cgi/content/full/jem.20072579/
DC1).   The Western blot shown in   Fig. 7 A   (and quantifi  ed 
in   Fig. 7 B  ) indicated that the RNA interference signifi  -
cantly reduced Ii protein expression, whereas MR1 protein 
expression remained stable in whole-cell lysates. However, sur-
face expression of MR1 was reduced     40% upon inhibiting 
Ii expression (  Fig. 7 C  ). By comparison, MHC class II ex-
pression was more aff  ected by reduced Ii expression, but class 
I expression of K  k   (not depicted) or L  d   (  Fig. 7 C  ) was unaf-
fected. Most strikingly, reduced Ii expression led to   >  80% 
inhibition of MAIT activation (  Fig. 7 D  ), whereas activation 
of the L  d   reactive T hybridoma L3 was unaff  ected (not de-
picted). Importantly, the consequences of Ii depletion look 
strikingly similar to the aforementioned CMA treatments, 
in that surface expression was less aff  ected than MAIT cell 
Although the physiological APC for MR1 antigen presenta-
tion is not known, in vivo studies demonstrated that B cells 
are required for the expansion and/or selection of MAIT 
cells (  2  ). However, no detectable surface expression of MR1 
was observed on isolated primary B cells or any other primary 
cells (unpublished data), probably because appropriate condi-
tions for inducing MR1 cell surface expression at levels suffi   -
cient to activate MAIT cells are not known (  8  ). To determine 
whether overexpression of transfected MR1 in B cell lines 
activates MAIT cells in a late endosome-dependent fashion, 
we used the vacuolar proton (H  +  ) ATPase inhibitors con-
canamycin A (CMA) and bafi  lomycin A1 (Baf A1) to prevent 
acidifi  cation of late endocytic compartments. It should be 
noted that these inhibitors have been shown to interfere 
with antigen presentation for CD1 isoforms and class II mol-
ecules (  30, 31  ). Surface expression of MR1 was reduced on 
CH27.mMR1 cells with the inhibitor CMA for 16 h, whereas 
surface expression of class Ia molecules was unaff  ected (  Fig. 6 A  ).   
Furthermore, leupeptin, which is known to block Ii proteol-
ysis and class II traffi   cking from the endosome to the surface 
(  32, 33  ), was found to similarly reduce MR1 surface ex-
pression by retaining MR1 in the late endocytic compart-
ments (Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20072579/DC1). More strikingly, MAIT cell stim-
ulation was ablated by CMA treatment of MR1-expressing B 
cells. As a negative control, activation of the alloreactive 
anti-L  d   hybridoma L3 (  34  ) was not aff  ected by CMA treat-
ment (  Fig. 6 B  ). Similar results were obtained using Baf A1 
(Fig. S3). Reduction of MR1 surface expression and abla-
tion of MAIT cell activation through inhibition of the vacu-
olar acidifi  cation strongly support the conclusion that MR1 
traffi   cs through the late endosomal/lysosomal compartments 
for antigen presentation. 
    Figure 6.     Inhibition of late endocytic compartments reduced MR1 
surface expression and blocked MAIT activation.   (A) CH27.mMR1 cells 
were treated with different concentrations of CMA and stained with indi-
cated antibodies with isotype-matched irrelevant antibodies as controls. 
The percentage of remaining surface expression compared with the DMSO 
solvent group was plotted. Data represent results from fi  ve experiments. 
(B) MR1-expressing cells treated with CMA were co-cultured with MAIT 
hybridoma 6C2, or L  d  -restricted hybridoma L3. The IL-2 production from 
CMA-treated groups was compared with the DMSO-treated group, show-
ing as remaining activity upon inhibition. Five experiments were done 
with similar results.     
    Figure 7.     Interference of Ii expression reduces MR1 surface ex-
pression on B cells and depletes MAIT cell activation.   CH27.mMR1 
cells were transduced with different shRNA (Fig. S4) to interfere with Ii 
expression. (A) Western blot of Ii in shRNA-transduced CH27.mMR1 cells 
(A  –  D) is compared with vector control (V), non-MR1  –  transduced B cells 
(CH27), and MR1-defi  cient fi  broblasts (FMR1     /    ). The blots shown for 
the major isoform p31 and cleaved fragment p10 are from two different 
exposures caused by differences in intensity. (B) Western blot results 
were quantifi  ed by the percentage of intensity of shRNA-transduced 
cells against the vector only. (C) With the best interference on Ii, shRNA-
C  –   and -D  –  transduced CH27.mMR1 cells were stained for intracellular 
Ii and surface MHC molecules. Results were plotted with the percent-
age of MFI against vector control. (D) shRNA- and vector-transduced 
CH27.mMR1 cells were used to activate MAIT cell hybridoma 6C2. Block-
ing with anti-MR1 mAb indicated that MAIT cell activation was MR1 
specifi  c. Data are representative of two experiments, and are shown as 
the mean   ±   the SD.     JEM VOL. 205, May 12, 2008 
ARTICLE
1207
lysosome, and the CRT  +   ER (  Fig. 8, A and B  ).   Both of these 
associations were found to be statistically signifi  cant when as-
sessed using Pearson ’  s coeffi   cient calculation ( Fig. 8 A ). ATPase 
inhibitor CMA-treated CH27.mMR1.EGFP cells displayed a 
  “  donutlike  ”   topology of swelled late endocytic compartments 
with intensive mMR1.EGFP staining, further confi  rming that 
a major subcellular location of MR1 is in the late endocytic 
compartments (Fig. S6). In addition, immunoelectron micros-
copy demonstrated that MR1 primarily localizes to ER tubu-
lar structures (  Fig. 8 C  ) and endocytic compartments (  Fig. 8 
D  ), especially late endosomes as exemplifi  ed by their multive-
sicular bodies (  Fig. 8 E  ). MR1 localization in multivesicular 
endosomes corroborates its dysfunction upon blocking of en-
dosomal acidifi  cation. These data demonstrate that MR1 traf-
fi  cs through and likely binds ligand in a late endocytic 
compartment, as shown in the schematic model (  Fig. 8 F  ), but 
activation (  Fig. 6  ). These combined fi  ndings provide com-
pelling evidence that surface MR1 expression is less depen-
dent on endosomal traffi   cking than MAIT cell activation. 
  B cell  –  expressed MR1 mainly localizes to the ER 
and endocytic compartments 
  To visualize the MR1 traffi   cking pathway and further confi  rm 
the importance of the late endosomal compartment, the fusion 
protein mMR1.EGFP expressed in B cells was localized using 
confocal microscopy in the context of ER and late endocytic 
markers, CRT or Lamp1, respectively. Of note, the intact 
mMR1 molecule on CH27.mMR1 and fusion protein on 
CH27.mMR1.EGFP activated MAIT cells similarly (Fig. S5, 
A and B, available at http://www.jem.org/cgi/content/full/
jem.20072579/DC1). Microscopy examination revealed that 
mMR1.EGFP mainly resided in the Lamp1  +   late endosome/
    Figure 8.     Late endosomal distribution of MR1 molecules in B cells visualized by confocal and cryoimmunoelectron microscopy.   (A)  CH27.
mMR1.EGFP was stained with antibodies against Lamp1 and CRT. The quantitation of colocalization between MR1 and Lamp1 or CRT was plotted to the 
right. The r and P values were obtained with the calculation used in   Fig. 5  . Staining was repeated three times with similar results. (B) Percentage of MR1 
colocalization in different compartments was plotted as the mean   ±   the SEM (C) CH27.mMR1.EGFP were stained with rabbit anti-EGFP antibody visual-
ized with 18-nm colloidal gold using electron microscopy. N, nuclear region. MR1 labeled by gold particles is shown at the tubular structures (arrow), 
plasma membrane (PM), or Golgi complex (G). (D) Some MR1 particles reside at the single vesicle (arrow), indicating an endosomal compartment. (E) More 
particles (arrow) localize in the multivesicular body (MVB) representing the late endosome compartments. (F) Schematic model of MR1 endocytic traffi  ck-
ing. MR1 egresses from the ER with either a surrogate ligand or association of Ii. The Ii facilitates MR1 traffi  c to late endocytic compartments to obtain a 
hypothetical ligand and further express onto the cell surface for MAIT cell activation. Bars: (A) 5   μ  m; (C  –  E) 200 nm.     1208 ANTIGEN PRESENTATION PATHWAY OF MR1 | Huang et al.
occur outside of the ER because the proteasome  –  TAP path-
way is the predominant provider of ER peptides for class I 
molecules (  24  ). It is also possible that association with the 
class I peptide loading complex could alter MR1 ligand bind-
ing and activation of other MAIT cell clones, in a manner 
similar to CD1 molecules that use both ER loading of a lipid 
ligand to activate V    14  -   NKT cells, and endosomal sam-
pling for V    14  +     i  NKT activation (  1, 2  ). Alternatively, MR1 
could bind a nonpeptide ligand such as a glycolipid. Indeed, 
Shimamura et al. reported that     GalCer-related synthetic 
glycolipids,     -mannosyl ceramide activates MAIT cells from 
a TCR transgenic mouse in what appeared to be an MR1-
dependent manner (  9, 10  ). However, this observation has 
been diffi   cult to reproduce with MAIT cell hybridomas used 
here (unpublished data). Structural comparisons of the MR1 
    /     domain sequences superimposed on the ligand binding 
platforms of class Ia and Ib molecules predict that if MR1 
does bind a peptide or a glycolipid, it does so using a unique 
anchoring scheme not shared with class Ia or CD1 proteins, 
respectively (  8  ). 
  Unexpectedly, MR1 was found to use a pathway with sim-
ilarities to class II molecules to enable effi   cient MAIT cell acti-
vation. For example, inhibition of vacuolar acidifi  cation 
reduced MR1 expression to     60% of untreated controls. This 
reduction was less than that seen with class II, but dramatically 
diff  erent than class Ia molecules, which were not aff  ected by 
inhibition. More strikingly, MAIT cell activation was pro-
foundly blocked by vacuolar H  +   ATPase inhibitors, to an ex-
tent not simply explained by decreased MR1 surface expression. 
For example, from previous studies we know that the 60% of 
maximal surface expression is suffi   cient to provide full MAIT 
cell activation (  6  ). These combined fi  ndings suggest that sur-
face expression of MR1 can be attained without endosomal 
traffi   cking; however, activation of these MAIT cell hybrid-
omas requires endosomal traffi   cking likely to bind a ligand. 
Furthermore, confocal studies suggest that MR1 localizes in 
Lamp1  +   late endocytic compartments, similar to class II mole-
cules. This localization was further confi  rmed via immunoelec-
tron microscopy by visualization of multivesicular endosomes 
containing a signifi  cant number of MR1 particles. Thus, like 
class II proteins, MR1 potentially samples ligands in endocytic 
compartments for MAIT cell activation. 
  Further support that MR1 uses an endocytic pathway for 
presentation is that MR1 is associated with Ii and this associa-
tion facilitates its endosomal localization. Importantly overex-
pression of MR1 with Ii greatly enhances MAIT cell activation. 
Reciprocally, interference of endogenous Ii expression in B 
cells, the presumed physiological mucosal APC, abrogated 
MAIT cell activation. These results strongly suggest that Ii 
chaperoning of MR1 facilitates its transport to endocytic com-
partments, which presumably contain the ligands required 
for activation of these MAIT cell hybridomas. This model is 
supported by the known role of Ii in promoting transport of 
class II through endocytic compartments to sample peptide lig-
ands (  12, 13  ). However, for certain class II ligands, Ii associa-
tion is not required (  13, 39  ). Accordingly, a reduced number 
do not exclude the possibility of a direct surface expression for 
the activation of other MAIT cell clones. 
    DISCUSSION   
  In this study, we present evidence that the class Ib molecule 
MR1 presents a ubiquitously expressed endogenous ligand 
that can activate MAIT cells via an endocytic pathway. Sup-
porting this notion, MAIT cell activation by MR1 does not 
require the MHC class I peptide loading complex, but is fa-
cilitated by the MHC class II chaperone Ii for endocytic traf-
fi  cking. This fi  nding is important in the context of studies of 
MHCII and CD1 isoforms, because binding of ligands in dif-
ferent endocytic compartments allows presentation of various 
endogenous or microbial ligands to         T cells that conse-
quently mount appropriate regulatory or eff  ector responses. 
  Although the nature of the MR1 ligand is not known, there 
is considerable evidence that presentation of an endogenous li-
gand is involved in MAIT cell activation. This evidence in-
cludes the following: (a) MR1 undergoes a conformational 
change from open to folded analogous to MHC molecules after 
binding a ligand (  35  –  37  ), and only antibodies to the folded 
MR1 conformation block MAIT cell activation; (b) extensive 
mutagenesis of the MR1 predicts that it interacts with ligand in 
a manner similar to classical MHC molecules (  6  ); and (c) low 
molecular weight components isolated from precipitated MR1 
are able to enhance MAIT cell activation in an MR1-depen-
dent manner (unpublished data). Furthermore, the endogenous 
ligand presented by MR1 is ubiquitously expressed, as sug-
gested by the observation that disparate cell lines overexpressing 
MR1 can activate select MAIT cell hybridomas in a manner 
independent of exogenous antigens. That the endogenous li-
gand presented by MR1 is able to activate MAIT cell hybrid-
omas, but not primary MAIT cells, probably results from 
insuffi   cient presentation or lack of adequate costimulatory sig-
nals on the transfectants. Similarly, in the absence of ligand, pri-
mary   i  NKT cells only respond to cells expressing very high 
levels of CD1d (  17, 30  ). Therefore, we used MAIT cell hybrid-
omas to study the pathway of endogenous antigen presentation. 
Indeed, studies of the CD1d endogenous ligand iGb3 clearly set 
a precedent for the presentation of an endogenous ligand in the 
context of a bacterial infection (  20, 38  ). Extending this analogy, 
MR1, like CD1d, might also be capable of direct presentation 
of an exogenous ligand of presumed gut fl  ora origin. 
  From previous studies of MHCI, MHCII, and CD1 iso-
forms, it is clear that molecular chaperones play key roles in 
determining intracellular traffi   cking, and thus their respective 
ligand acquisition. Unlike classical class Ia molecules, MR1 
expression and MAIT cell activation in vitro do not require 
proteasome function, TAP transporter, or the ER molecular 
chaperones tapasin and CRT. The lack of TAP dependency 
is consistent with the observation that the in vivo MAIT cell 
development is also TAP independent (  1, 2  ). In regard to the 
presentation pathway used by MR1, these fi  ndings suggest 
that MR1 does not require a peptide processed by the prote-
asome, or translocated into the ER by TAP. Therefore, if 
MR1 does bind a peptide, its processing and binding likely JEM VOL. 205, May 12, 2008 
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responses upon TCR ligation (  4  ). Indeed, MR1 inhibiting 
the pathogenesis in an EAE model provides the fi  rst evidence 
for its potential regulatory role in autoimmune responses (  5  ). 
The endocytic pathway used by MR1 for antigen presenta-
tion likely contributes to the secretion of both stimulating 
and inhibitory cytokines by MAIT cells, similar to the cyto-
kine production by diff  erent subsets of NKT cells (  42  ) or 
CD4  +   T cells. Regardless of the physiological function of 
MAIT cells, the ability of MR1 to sample endogenous or 
induced-endogenous ligands is likely an integral factor deter-
mining how MAIT cells control the balance of homeostatic 
versus autoimmune responses. 
    MATERIALS AND METHODS   
  Cell lines.     Mouse B6 (H2b) embryonic fi  broblast WT3, and fi  broblasts defi  -
cient for TAP1 (FT1    –    or TAP      /     ), tapasin (Tpn      /     ), CRT (K42 or CRT      /     ), 
or K  b  /D  b   (KODO) were used for transduction (  23  ). Ltk    –    transfected with 
I-A  d   (A  d  .WT2), A  d   and genomic Ii sequence (A  d  .gIi), or A  d   genomic Ii se-
quence, and H-2DM      and      chains (A  d  .IiDM) have been previously de-
scribed (  13  ). Mouse B cell line CH27 (H-2  a  ) (  43  ) was a gift from P. Allen 
(Washington University, St. Louis, MO). MAIT T-T hybridoma cells, 6C2, 
and 8D12, have been described previously (  1, 6  ). CD8  +   T hybridoma (L3) 
(  34  ) specifi  cally reactive to H-2L  d   molecule was a gift from O. Kanagawa 
(Washington University, St. Louis, MO). We generated MR1-defi  cient em-
bryonic fi  broblast FMR1      /      from MR1      /      mice (  2  ). All cells were main-
tained as previously described (  6  ). 
  Gene cloning and retroviral transduction.     Generation of the mMR1 
and mMR1/L  d   molecules was previously reported (  6, 22  ). Fusion protein 
mMR1.EGFP was generated using three-piece ligation of PCR-amplifi  ed 
mMR1, and EGFP genes with the vector pMX.IRES.Puromycin modi-
fi  ed from pMX retroviral expression system (  44  ). Retrovirus-containing 
supernatants were generated and used for transduction as previously de-
scribed (  6  ). 
  Antibodies.     Anti-mMR1 mAb 12.2, 26.5, and 4E3 were previously de-
scribed (  22  ), as were mAb B8-24-3 (anti-Kb; American Type Culture Col-
lection), mAb 30  –  5-7 (anti-Ld) L  d   (  45  ), and mAb K24-199 (I-A  d  ) (  13  ). The 
new anti-MR1 mAb 6D1 (unpublished data) was used for Western blot. 
mAb 34  –  2-12 (anti-D  d  ), PE-labeled 11  –  5.2 (I-A  k  ), FITC-labeled AF3-12.1 
(anti-K  k  ), mAb 34  –  5-3 (I-A  d  ), In-1 (anti  –  mouse Ii), biotinylated mIgG2a, 
and Fc receptor blocker were purchased from BD Biosciences. Rabbit anti  –
  H-2DM was used for immunoprecipitations and blotting, as previously de-
scribed (  28  ). Mouse anti  –      -actin AC-74 (Sigma-Aldrich) was used as a 
loading control in Western blots. For confocal microscopy, rat anti  –  mouse 
Lamp1 1D4B (IgG2a) was purchased from BD Bioscience, and rabbit anti-
CRT SPA-600 was obtained from Stressgen. Alexa fl  uor  –  conjugated sec-
ondary antibodies were purchased from Invitrogen. 
  Proteasome or lysosome inhibition.     Proteasome inhibitors lactacystin 
(Alexis), NLVS (  26  ), drug BFA (Epicentre), and vacuolar H  +   ATPase inhib-
itors CMA (Calbiochem) and bafi  lomycin A1 (Sigma-Aldrich) (  30, 31  ) were 
used to treat MR1-expressing cells for 16 h. 
  Flow cytometry.     The MR1-transduced fi  broblasts were analyzed using a 
FACSCalibur (BD Biosciences) as previously reported (  6  ). B cells were 
treated with Fc receptor blocker before applying biotinylated 26.5 or 30  –  5-7 
with biotinylated mIgG2a as an isotype control. Intracellular staining of Ii 
was performed by using biotinylated In-1 antibody after fi  xing cells with 2% 
paraformaldehyde and permeabilizing with 1% saponin. 
  MAIT cell activation.     10  5   mMR-expressing cells/ml were co-cultured 
with 10  6  /ml MAIT hybridoma cells for 24 h, and the secreted IL-2 was 
of CD4  +   T cells develop in Ii-defi  cient mice, and interestingly, 
they display a more self-reactive phenotype (  39, 40  ). 
  Ii also facilitates antigen presentation by certain CD1  –  lipid 
complexes. Although Ii promotes endosomal traffi   cking and li-
gand acquisition by the CD1d isoform, this role is redundant 
with sorting sequences in its cytosolic tails (  16  ). For example, Ii 
is able to enhance V    14  +     i  NKT cell activation by tailless CD1d 
molecules, and Ii-defi  cient cells exhibit impaired activation of 
V    14  +     i  NKT cells, but not V    14  -   NKT cells. Interestingly, 
activation of V    14  +     i  NKT requires an endosome-derived li-
gand, whereas V    14  -   NKT cells are activated by tailless CD1d 
that are likely loaded a ligand through the secretory pathway 
(  16, 20  ). Similarly, Ii appears to play a prominent role in the 
presentation of certain, but not all MR1 ligands. This conclu-
sion is based on our observation the lack of Ii expression has 
only a minimal eff  ect on MR1 surface expression, but a pro-
found eff  ect of MAIT hybridoma cell activation. Furthermore, 
like with   i  NKT cells, MAIT cell development is Ii independent 
(  3  ). However, analogous to the development of CD4  +   T cells, 
the absence of Ii could alter the ligand specifi  city of developing 
MAIT cells, skewing it toward increased self-reactivity. Indeed, 
consistent with this speculation, the self-reactive MAIT cell hy-
bridomas characterized in this study were isolated from Ii- (and 
TAP-)defi  cient mice. In contrast, our attempts thus far using 
MR1 overexpressing cell lines to stimulate primary MAIT cells 
or hybridomas generated from the V    19  i   transgenic mice have 
been negative (unpublished data). But regardless of whether the 
MR1 ligand is from an endogenous or exogenous source, the 
studies here demonstrate that MR1 can present ligand from an 
endocytic compartment to MAIT cells. 
  Physiological models proposed to explain MR1 function 
can now incorporate the fact that MR1 traffi   cs through an 
endocytic compartment. It has been shown that MAIT cell 
development is dependent on the presence of MR1, com-
mensal fl  ora, and the BCR J  H   chain, but neither B1 B cells, 
the      chain, nor isotype switching (  21  ). A likely candidate for 
mediating MAIT cell expansion is B2 B cells, especially the 
subset expressing IgA in the gut (  21  ). It could be envisioned 
that MR1 presentation to MAIT cells may be a negative 
feedback loop to temper IgA secretion (  2, 21  ). Upon endo-
cytosis of microbial components during bacterial transloca-
tion from the gut lumen into submucosal tissues, B cells start 
producing IgA and inhibiting bacterial translocation. This 
process is exemplifi  ed in the     MT mice, which harbor IgA-
producing B cells and have a normal MAIT cell population 
(  21, 41  ). MR1 expressed by B cells may have the potential to 
load endogenous ligands in endosomal compartments induced 
by the commensal bacteria. Alternatively, MR1 may also be 
capable of directly binding a gut bacteria-specifi  c ligand pro-
cessed in an endocytic compartment. Either of these models 
is consistent with the hypothesized interaction between these 
B cells and MAIT cells for gut immune regulation or MAIT 
cell development (  2, 21  ). The fact that primary MAIT cells 
from V    19  i   transgenic mice rapidly secrete cytokines, includ-
ing IL-4, -5, and -10, and up-regulate ICOS expression indi-
cate that MAIT cells can initiate Th2-like or inhibitory 1210 ANTIGEN PRESENTATION PATHWAY OF MR1 | Huang et al.
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tested as previously described (  6  ). Purifi  ed anti-mMR1 mAb was used to 
block MAIT activation at 10   μ  g/ml. The recombinant mouse IL-2 (Bio-
source) was used to generate a standard curve. 
  Immunoprecipitations and Western blots.     As previously described (  22  ), 
we used anti-MR1 antibody mAb 26.5 coupled with protein A  –  Sepharose 
6MB (Sigma-Aldrich) to precipitate mMR1 and anti-Ii (In-1) bound with 
GammaBind G  –  Sepharose (GE Healthcare) to precipitate mouse Ii. For 
Western blots, MR1 was detected by mAb 4E3 or 6D1 as previously de-
scribed (  6  ), whereas Ii was stained by biotinylated In-1. Results of Western 
blot were quantifi  ed using ImageJ software (National Institutes of Health). 
  RNA interference of Ii molecule.     The retroviral shRNA expression vec-
tor pSRPU6 vector was modifi  ed from pSUPER.retro.puro (OligoEngine) 
by replacing the H1 promoter with the human U6 promoter. This newly 
constructed vector was tested with high effi   ciency for inducing small inter-
ference RNA (siRNA) to block GFP expression. CH27 cells transduced 
with mMR1 were further infected with retrovirus expressing siRNA as se-
lected in the Fig. S4. Infected cells were screened with 4   μ  g/ml puromycin 
and tested with Western blot, FACS, and MAIT cell activation 3  –  7 d after 
antibiotics selection. 
  Confocal microscopy and image analyses.     CH27.mMR1.EGFP cells 
were grown on Laboratory-Tek chambered coverglass slides (Nalge Nunc), 
stained with anti-Lamp1 or CRT antibodies, and observed using LSM510 
META Laser Scanning Confocal Microscope (Carl Zeiss, Inc.) as previously 
reported (  46  ). Negative control used isotype matching irrelevant rat or mouse 
mAbs or purifi  ed preimmune rabbit serum. Images were processed with LSM 
image browser and analyzed with the software Volocity 4.0 (Improvision). Co-
localization of MR1 with Lamp1 and CRT molecules was analyzed by testing 
each pixel for the presence of both green (mMR1.EGFP) and red colors under 
the same threshold for multiple cells. Pearson  ’  s coeffi   cient (r) for each cell was 
calculated by Volocity (  47  ), and the signifi  cance of this coeffi   cient was tested 
with the sample size. The percentage of colocalization of MR1 with Lamp1 
or CRT was calculated with measurement module from the Volocity, and 
the paired Student  ’  s   t   test was used to examine the signifi  cance of diff  erence 
between groups. 
  Cryoimmuno electron microscopy.     CH27.mMR1.EGFP cells were 
fi  xed in 4% paraformaldehyde (Polysciences, Inc.) and 0.01% glutaraldehyde 
(Polysciences, Inc.). Ultrathin sections were stained with rabbit anti-EGFP 
antibody and followed by the goat anti  –  rabbit IgG conjugated to 18-nm 
gold (Jackson ImmunoResearch Laboratories) as previously reported (  46  ). 
Staining with the secondary conjugate only and the CH27.mMR1 were 
used as negative controls. Staining was observed with the JEOL 1200EX 
transmission electron microscope (JEOL USA). 
  Online supplemental material.     Fig. S1 shows that the MR1 protein is 
ubiquitously expressed in diff  erent mouse cell lines and tissues, as determined 
by the immunoprecipitation and Western blot. Fig. S2 shows that treatment 
of cells with leupeptin down-regulates the MR1 surface expression, impairs 
Ii processing, and retains MR1 in late endocytic compartments. Similar to 
fi  ndings shown in   Fig. 6   using CMA, Fig. S3 shows that another H  +   ATPase 
inhibitor, bafi   lomycin A1, reduces MR1 surface expression and inhibits 
MAIT cell activation. Fig. S4 shows the siRNA sequences used for interfer-
ing with endogenous Ii expression. The data shown in Fig. S5 demonstrates 
that adding EGFP to the C terminus of MR1 protein does not impact on its 
surface expression or ability to activate MAIT cells. Fig. S6 shows swollen 
late endocytic compartments with MR1 accumulation upon applying the 
inhibitor CMA. The online version of this article is available at http://www
.jem.org/cgi/content/full/jem.20072579/DC1. 
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